menu
    • menu
    [{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"GV101","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"GV101","moa":"ROCK2","graph1":"Neurology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Ovid Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Ovid Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Graviton Bioscience

    Menu

    Graviton Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Graviton Bioscience

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Graviton Bioscience

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GV101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Graviton Receives Sanofi Investment to Advance Next-Generation ROCK2 Inhibitors

                            Details : Through financing, Sanofi gains a right of first negotiation to license compounds like GV101 for various indications, including immunological and metabolic syndrome.

                            Product Name : GV101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 02, 2024

                            Lead Product(s) : GV101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Graviton Bioscience

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Graviton Bioscience

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GV101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ovid Therapeutics

                            Deal Size : $10.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhib...

                            Details : The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.

                            Product Name : GV101

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            January 05, 2023

                            Lead Product(s) : GV101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ovid Therapeutics

                            Deal Size : $10.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth